Contract analysis

I. Executive Summary In connection with the proposed $140,000,000 asset purchase of the OncuPath™ companion diagnostics assay line by Meridian Precision Diagnostics, Inc. ("Buyer" or "Meridian" or "MPD") from our client, Genome Dx Therapeutics Inc. ("Seller," "GDT," or the "Company"), a buyer-side representations and warranties insurance ("RWI") policy has been procured from Apex Mutual Insurance Company (the "Insure

II. Background and Transaction Context To provide the appropriate framework for analyzing the RWI policy, we summarize below the key parties, transaction structure, and relevant background facts. Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121. GDT is a portfolio company of Pinnacle Biosciences Partners Fund III, L.

III. APA Indemnification Structure — Overview

Article IX of the APA establishes a comprehensive indemnification framework governing post-closing claims by Buyer against Seller for breaches of representations and warranties, breaches of covenants, and certain specified indemnified matters. Understanding the APA indemnification structure is essential to evaluating the RWI policy's coverage and identifying any gaps between contractual indemnification and insurance

IV. RWI Policy — Key Terms This section summarizes the material terms and conditions of the RWI policy procured by Buyer from Apex Mutual Insurance Company. A. Insurer and Policy Identification The RWI policy has been procured from Apex Mutual Insurance Company, a New York-domiciled insurance company. Apex Mutual is a well-established insurer in the transactional risk insurance market, with a current A.M. Best rating

V. Known-Matters Exclusions A. Definition of "Known Matters" The RWI policy contains a standard "known matters" exclusion, which excludes from coverage any loss arising from matters actually known to the deal team of the named insured (Buyer) prior to the policy inception date that would reasonably be expected to give rise to a claim under the policy. The "deal team" for purposes of the known-matters exclusion is def

1. Pre-Closing Environmental Liabilities. Environmental liabilities associated with GDT's facilities that are not being conveyed as part of the purchased assets. This exclusion relates to any known or potential environmental contamination, remediation obligations, or regulatory compliance issues at GDT facilities other than the CLIA-certified reference laboratory being transferred.

2. Pending Litigation Matters. Litigation matters disclosed in the Disclosure Schedules to the APA, including any pending or threatened lawsuits, arbitrations, or administrative proceedings identified in Schedule 4.10 (Litigation) as of the signing date.

3. OncuPath-HER3™ PMA Supplement (P230014). Any issues relating to the pending PMA supplement for OncuPath-HER3™, which was submitted to the FDA on January 30, 2023, and remains under review. The Insurer has identified potential regulatory outcome uncertainty associated with this submission, including the risk of a refusal to file, a request for additional clinical data, or an unfavorable FDA determination. The Insur

4. Patent Chain-of-Title Deficiencies. Any known deficiencies, gaps, or irregularities in the chain of title for any of the 14 issued United States patents or 7 pending patent applications identified during intellectual property due diligence. To the extent that specific chain-of-title issues were flagged in the IP diligence report and disclosed in the Disclosure Schedules, those matters are excluded.

5. CLIA Certificate Non-Compliance. Any disclosed non-compliance issues relating to the CLIA certificate for the reference laboratory located at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 (CLIA ID: 05D2178493). If CLIA inspection deficiencies, corrective action plans, or regulatory correspondence were disclosed during diligence, those matters fall within the known-matters exclusion. C. Impact on

VI. Standard Exclusions and Limitations In addition to the known-matters exclusions discussed in Section V above, the RWI policy contains a number of standard exclusions and limitations that are customary in buyer-side RWI policies. These exclusions are generally non-negotiable and reflect the Insurer's underwriting position on categories of risk that it is unwilling to assume. Each exclusion is summarized below, alo

VII. Interplay Between RWI Policy and APA Indemnification The RWI policy and the APA indemnification framework are designed to operate in concert, with the policy functioning as the primary recovery mechanism for Buyer and the APA indemnification (including the escrow) serving as a secondary or backup source of recovery. This section analyzes the key points of interplay between the policy and the APA indemnification

VIII. Coverage Gaps and Risk Areas for Seller Despite the significant risk-transfer benefits provided by the buyer-side RWI policy, several coverage gaps and risk areas remain for Seller. Each of these gaps represents a scenario in which Buyer may be unable or unwilling to recover from the RWI policy and instead pursue direct indemnification claims against Seller. This section identifies and analyzes the six most sig

IX. Premium Allocation and Payment Mechanics The total premium for the RWI policy is $840,000, calculated as 3% of the $28,000,000 aggregate policy limit. The premium is allocated equally between Seller and Buyer, with each party responsible for $420,000 (50% of the total premium). This allocation was negotiated during the term sheet phase and is consistent with prevailing market practice for buyer-side RWI policies,

X. Process and Binding Confirmation RWI Placement Process. The RWI policy was procured through a buyer-led placement process, which is customary for buyer-side RWI policies. Buyer's insurance broker, in coordination with Buyer's counsel (Whitfield Sayer & Gregg LLP), solicited RWI proposals from multiple insurers and ultimately selected Apex Mutual Insurance Company based on pricing, coverage terms, and the insurer's

XI. Recommendations for Seller Based on our analysis of the RWI policy, the APA indemnification structure, and the identified coverage gaps, we provide the following recommendations to protect Seller's interests in connection with the RWI policy and the closing of the transaction. A. Confirm Anti-Subrogation Language Calderwood & Harkness LLP should verify that the RWI policy's subrogation waiver explicitly covers th